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____________ 
 
OPINION* 
____________ 
 
 
HARDIMAN, Circuit Judge. 
 This appeal involves a longstanding battle between two companies: Sunrise 
Pharmaceutical, Inc. and Vision Pharma, LLC. Initially, Vision sued Sunrise and issued a 
press release about the lawsuit. Sunrise viewed the press release as “false and 
defamatory,” so it sued Vision years later. App. 20. The District Court dismissed 
Sunrise’s complaint, holding that the Noerr-Pennington doctrine barred Sunrise’s claims. 
We will affirm the District Court’s order on the alternative ground that Sunrise failed to 
plausibly plead a right to relief. 
 
 * This disposition is not an opinion of the full Court and pursuant to I.O.P. 5.7 
does not constitute binding precedent. 
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I 
 In its lawsuit against Vision, Sunrise alleged unfair competition and false 
advertising under the Lanham Act, unfair competition under state statutory and common 
law, tortious interference with prospective economic relations, and trade libel.1 Its 
complaint deemed “false and defamatory” the following statements in Vision’s press 
release: 
44. . . . Vision Florida falsely states that Sunrise “defective[ly] 
manufacture[d] . . . certain drug products deemed adulterated and unsalable 
by the U.S. Food & Drug Administration.” 
 
45. . . . Vision Florida falsely states that Sunrise “willful[ly]” sold 
“adulterated drugs to Vision Pharma.” 
 
46. . . . Mr. Busman, who is listed as the “Founder, President & CEO” of 
“Vision Pharma,” also defames Sunrise, as he is quoted as stating that the 
false and defamatory statements [sic] resulted in “severe damage” to Vision 
Florida, and that the company filed a lawsuit based on those false and 
defamatory statements “for a well-deserved victory.” 
 
App. 27–28.  
 Vision moved to dismiss Sunrise’s complaint, claiming that the statements in the 
press release were true or, alternatively, the Noerr-Pennington doctrine barred Sunrise’s 
claims. Under the Noerr-Pennington doctrine, “[t]hose who petition [the] government for 
 
 1 Sunrise also alleged unlawful monopolization and attempted monopolization in 
violation of the Sherman Act and the Clayton Act, and state statutory law, but did not 
appeal the District Court’s dismissal of those claims. 
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redress are generally immune from antitrust liability.” Prof. Real Estate Inv’rs, Inc. v. 
Columbia Pictures Indus., Inc. (PRE), 508 U.S. 49, 56 (1993). Vision argued the doctrine 
applies even to claims not arising under the antitrust laws and immunizes it from liability 
for statements in the press release.  
 The District Court granted Vision’s motion. It ruled the Noerr-Pennington doctrine 
immunizes Vision from liability for the statements in the press release unless Vision’s 
lawsuit against Sunrise was objectively baseless. Finding Vision’s lawsuit was not baseless, 
it held Noerr-Pennington barred Sunrise’s claims. Sunrise moved for reconsideration and 
the Court denied the motion. Sunrise timely appealed. 
II2 
 We review de novo the District Court’s order dismissing Sunrise’s claims under 
Rule 12(b)(6) of the Federal Rules of Civil Procedure. Phillips v. Cty. of Allegheny, 515 
F.3d 224, 230 (3d Cir. 2008). “We may affirm the district court on any ground supported 
by the record.” Tourscher v. McCullough, 184 F.3d 236, 240 (3d Cir. 1999) (citations 
omitted). 
 We need not address the District Court’s Noerr-Pennington analysis because the 
record demonstrates that Sunrise failed to plead a plausible cause of action. Sunrise says 
 
 2 The District Court had jurisdiction under 28 U.S.C. § 1332(a)(1). We have 
jurisdiction under 28 U.S.C. § 1291. 
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its claims “sound[] in defamation,” Sunrise Br. 10, yet it failed to plausibly plead that 
Vision made a false statement. See, e.g., DeAngelis v. Hill, 180 N.J. 1, 13 (2004).  
 We first identify Sunrise’s averments that are merely legal conclusions not entitled 
to the presumption of truth. See Ashcroft v. Iqbal, 556 U.S. 662, 679 (2009). These 
include Sunrise’s allegations, in paragraphs 44–46 of its complaint, that certain 
statements in the press release were “false and defamatory.” App. 27–28. Next, we ask 
whether there are any well-pleaded factual allegations that plausibly give rise to an 
entitlement to relief. See Iqbal, 556 U.S. at 679. Sunrise’s complaint contains no such 
facts. Notably, Sunrise did not plead facts suggesting its drugs were properly 
manufactured or that the FDA erred in deeming its drugs adulterated and unsalable. Nor 
did it plead facts suggesting that, if its drugs were adulterated, it did not sell them 
willfully or Vision did not suffer severe damage. 
 In sum, Sunrise’s allegation that Vision made false statements is a “naked 
assertion[] devoid of further factual enhancement,” Iqbal, 556 U.S. at 678, insufficient to 
survive a motion to dismiss. So we will affirm the District Court’s order dismissing 
Sunrise’s complaint. 
